Upharmacia July 2017
PHARMA
MARKET NEWS
Sanofi-Aventis Ukraine became a Victim of Fraudsters
Fraudsters have transferred UAH 46 mio from the accounts of Sanofi-Aventis Ukraine through forgery of documents of the Economic Court of Kyiv .
The company stated that the crime was conducted with the connivance of representatives of the judiciary system of Ukraine .
“ It damages not only the company but also the reputation of Ukraine as a state , which struggles to attract foreign investments and declares their protection ,” the company ’ s official stated . “ The lack of adequate protection of our rights can negatively affect the further plans on development of Sanofi Group ’ s business in Ukraine ”.
Sanofi-Aventis Ukraine declared the hopes for prompt reaction from the competent authorities to return the funds and bring perpetrators to justice . The company also considers the possibility of appealing to international mechanisms on protecting the rights of foreign investors .
In 2016 , Sanofi-Aventis Ukraine held 6 th position on retail drug market of Ukraine .
The MOH Urges Companies to Re-register Drugs with Russian Certificates
The MoH appealed pharmaceutical companies , which operate in Ukraine , urging them to re-register drugs with registration certificates obtained in Russia .
This measure is aimed to ensure the quality of drugs on Ukrainian market .
The range of companies ( Servier Ukraine , Grindeks , Johnson & Johnson Ukraine , Teva Ukraine ) submitted the letter to the MOH , expressing the obligation to make changes to the registration materials .
In Apr 2017 , acting Head of the MoH declared the intention to prohibit circulation of Russian drugs and medical devices in Ukraine due to their “ doubtful quality ”. Currently , the MOH do not approve registration or re-registration of drugs and medical devices produced in Russia .
MSD Failed to Find Sites for Localization in Ukraine
The US-based pharmaceutical company MSD was trying to find production sites in Ukraine for localization of their products . The Head of Innovation Drugs Department of MSD Ukraine Margarita Ognivenko stated that the company failed to find production sites compliant with MSD standards . However , earlier the company has successful cooperation with Ukrainian company on delegated production of PegIntron ® ( peginterferon alfa-2b ).
This year MSD started suppling KEYTRUDA ® ( pembrolizumab ) in Ukraine , first immuno-oncology drug on local marker . In 5M2017 , MSD ( under Merck & Co brand name ) held 7 th position on Ukrainian hospital market . Its best-selling drugs were Cancidas ® and Noxafil ® .
MSD plans to accelerate its hospital sales in Ukraine and to launch new antibiotics , oncology drugs and viral preparations . The company is also implementing project on rational use of antibiotics in Ukrainian clinics .
Bayer Won the Patent Dispute in the Court
Economic Court of Kyiv satisfied the appeal of Bayer on violation of intellectual property rights of the company by Indian company Symed Labs Limited . In Jul , State Expert Center addressed to the MOH the registration application of Symed Labs for the drug Rivaroxaban .
Bayer appealed the Court asking to prevent the registration of the Indian drug , as the corresponding INN had been registered by Bayer in 2013 under the brand name Xarelto ®. Thus , the Court prohibited the MOH to register rivaroxaban generic of Symed Labs Limited .
In Jun , Bayer submitted the similar appeal regarding illegal registration of another rivaroxaban generic by Dr . Reddy ’ s .
Farmak Has Changed the CEO
Farmak has changed its top management on July 03rd , 2017 . Filya Zhebrovskaya , the owner of the company , has left the post of the CEO and became Chairman of the Supervisory Board .
Augustin Dubnicka was appointed Farmak ' s new CEO . Mr . Dubnicka
6 www . upharma-c . com